The three-year agreement, which totals $13.7 million, calls for collaboration between Takeda and a team of world-renowned scientists led by BIDMC Chief Academic Officer Jeffrey S. Flier, M.D. Principal investigators include BIDMC Chief of Endocrinology Barbara Kahn, M.D., Bradford Lowell, M.D., Ph.D., Joel Elmquist, D.V.M., Ph.D., Anthony Hollenberg, M.D. , and BIDMC Chief of the Division of Signal Transduction Lewis Cantley, Ph.D.
Independently, each of the members of the BIDMC team is a leader in the fields of endocrinology and metabolic disease, having extensively investigated the molecular basis of leptin resistance in obesity, the cellular and molecular mechanisms for insulin resistance in diabetes, and the role of the brain to hunger and satiety. Over the past year alone, these investigators have published more than 45 papers in the world's leading scientific journals, including Science, Nature, Cell, and The New England Journal of Medicine.
Takeda Chemical Industries, an industry leader in the development of diabetes therapies, is Japan's largest pharmaceutical firm and one of the 15 largest pharmaceutical companies worldwide. More than 1,000 researchers at Takeda carry out world-class research using advanced technology in such fields as human genetics, receptors, and enzymes.
"We are extremely pleased and honored to enter into this collaboration with Beth Israel Deaconess Medical Center," said Takashi Soda, Ph.D., General Manager of Takeda's Pharmaceutical Research Division. "In choosing this partnership, we will be collaborating with one of the most prominent and accomplished groups of
Contact: Bonnie Prescott
Beth Israel Deaconess Medical Center